Table 1. Proportions of Parkinson's Disease Patients Prescribed Anti-Parkinson Drugs.
| 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | ||||||||
| (n = 110) (%) | (n = 154) (%) | (n = 144) (%) | (n = 263) (%) | (n = 315) (%) | (n = 353) (%) | P-value c | |||||||
| Age, median, IQR | 60, 53–70 | 63, 53–75 | 64, 52–76 | 60, 49–72 | 57, 47–63 | 56, 46–62 | - | ||||||
| Gender (male), N (%) | 55 | (50.0) | 71 | (46.1) | 68 | (47.2) | 133 | (50.6) | 163 | (51.7) | 180 | (51.0) | |
| Parkinson's disease duration (months) median, IQR | 24, 10–60 | 29, 11–62 | 38, 13–67 | 29, 10–67 | 23, 7–61 | 22, 7–52 | - | ||||||
| L-dopa | |||||||||||||
| Levodopaa | 64 | (58.2) | 85 | (55.2) | 76 | (52.8) | 144 | (54.8) | 158 | (50.2) | 180 | (51.0) | 0.114 |
| Ergot dopamine agonists | |||||||||||||
| Cabergoline | 25 | (22.7) | 34 | (22.1) | 25 | (17.4) | 30 | (11.4) | 29 | (9.2) | 22 | (6.2) | <0.001 |
| Pergolide | 12 | (10.9) | 10 | (6.5) | 6 | (4.2) | 12 | (4.6) | 12 | (3.8) | 14 | (4.0) | 0.008 |
| Bromocriptine | 9 | (8.2) | 10 | (6.5) | 9 | (6.3) | 17 | (6.5) | 17 | (5.4) | 13 | (3.7) | 0.050 |
| Non-ergot dopamine agonists | |||||||||||||
| Pramipexole | 9 | (8.2) | 17 | (11.0) | 16 | (11.1) | 62 | (23.6) | 88 | (27.9) | 99 | (28.0) | <0.001 |
| Ropinirole | 0 | (0.0) | 0 | (0.0) | 3 | (2.1) | 16 | (6.1) | 32 | (10.2) | 29 | (8.2) | <0.001 |
| Talipexole | 1 | (0.9) | 2 | (1.3) | 2 | (1.4) | 9 | (3.4) | 5 | (1.6) | 4 | (1.1) | 0.989 |
| Anticholinergics | |||||||||||||
| Trihexyphenidyl | 21 | (19.1) | 32 | (20.8) | 31 | (21.5) | 53 | (20.2) | 67 | (21.3) | 88 | (24.9) | 0.174 |
| Biperiden | 7 | (6.4) | 9 | (5.8) | 7 | (4.9) | 21 | (8.0) | 25 | (7.9) | 22 | (6.2) | 0.647 |
| Other anticholinergicsb | 0 | (0.0) | 1 | (0.6) | 1 | (0.7) | 4 | (1.5) | 1 | (0.3) | 1 | (0.3) | - |
| Others | |||||||||||||
| Amantadine | 33 | (30.0) | 41 | (26.6) | 42 | (29.2) | 53 | (20.2) | 69 | (21.9) | 78 | (22.1) | 0.029 |
| Selegiline | 12 | (10.9) | 20 | (13.0) | 21 | (14.6) | 33 | (12.5) | 40 | (12.7) | 37 | (10.5) | 0.528 |
| Droxidopa | 9 | (8.2) | 12 | (7.8) | 15 | (10.4) | 19 | (7.2) | 16 | (5.1) | 16 | (4.5) | 0.021 |
| Entacapone | 0 | (0.0) | 0 | (0.0) | 4 | (2.8) | 17 | (6.5) | 31 | (9.8) | 31 | (8.8) | <0.001 |
| Zonisamide | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 3 | (1.0) | 11 | (3.1) | <0.001 |
a
Levodopa alone and combination of levodopa with dopa-decarboxlyase inhibitor.
b
Other anticholinergics include piroheptine, profenamine, and mazaticol.
c
Cochran-Armitage trend test was used to calculate P-values (Statistical significance level was set at P<0.002 after Bonferroni correction).
The total proportion of prescribed anti-Parkinson drugs is not 100% due to the presence of plural drug users.